Connect with us

Biotech

Iñaki Berenguer Adds Valencian Investors to LifeX Ventures Biotech Fund

LifeX Ventures already has 12 startups in its portfolio (nine US and three European) and plans to raise this figure to a maximum of 45. For Berenguer, the participation of GoHub Ventures “is a great honor and a sign that in Spain there are also VCs that support the most cutting-edge innovation.”

Published

on

The entrepreneur and investor from Alicante, Iñaki Berenguer, is in trend among large Valencian institutional investors. Just a few days ago, Angels, the investment vehicle of the president of Mercadona, Juan Roig, announced the acquisition of a minority stake in his LifeX Ventures biotech fund, and now it is GoHub, from the Global Omnium group, who has joined as a minority investor.

In the case of the investment firm of the group linked to the water sector, it will be the first investment of its second fund in the United States, GoHub Ventures II.

The LifeX Ventures fund is a $100 million venture capital vehicle managed by Iñaki Berenguer (who has accumulated successes in startups such as Pixable, Contactive, Coverwallet) and the American Amol Sarva (Halo Neuroscience, Knotable, and Knotel). The purpose of LifeX Ventures is to invest in technologies that prolong people’s lives and help solve the global environmental challenge.

LifeX Ventures’ mission is to invest in innovative companies

GoHub Ventures II operates as an independent fund, regulated by the National Securities Market Commission (CNMV), and is the second investment vehicle of GoHub, which thus reaffirms its international vocation, its commitment to the most successful local entrepreneurs, and the diversification of its investment portfolio, whose core will continue to be highly technological startups with B2B SaaS business models and exponential scalability based on its product, vision, and strategy.

The mission of LifeX Ventures is, in Berenguer’s words, “to commercialize the latest scientific advances that today sound like science fiction so that anyone can be treated, cured, and monitor their recovery at an affordable price” thanks to the most sophisticated software and artificial intelligence. The biotech sector, predicts the Valencian, “will be where many of the world leaders of the next four or five years will emerge.”

Inés Calabuig, director of GoHub Ventures, stated that LifeX Ventures fund’s strategy consists of “investing not only in technology startups in verticals such as Enterprise Software, Cloud Infrastructure, Artificial Intelligence or Web3, but also in diversifying through alliances with other venture capital funds in areas with immense growth potential and a clear impact on the welfare of people and care for the planet (Climate Tech)”.

Calabuig said that “a new investment will be announced soon” and that the team “continues to work to find good opportunities both in Europe and in the US and Latin America”.

The first investees of LifeX Ventures

LifeX Ventures already has 12 startups in its portfolio (nine US and three European) and plans to raise this figure to a maximum of 45. For Berenguer, the participation of GoHub Ventures “is a great honor and a sign that in Spain there are also VCs that support the most cutting-edge innovation”.

__

(Featured image by Themil via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in elEconomista.es, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Anthony Donaghue writes about science and technology. Keeping abreast of the latest tech developments in various sectors, he has a keen interest on startups, especially inside and outside of Silicon Valley. From time to time, he also covers agritech and biotech, as well as consumer electronics, IT, AI, and fintech, among others. He has also written about IPOs, cannabis, and investing.

Continue Reading